SCHEMBL23160282

SCHEMBL23160282

O=C1c2ccc(Cl)cc2CCCN1CC(O)CN1CCc2ccccc2C1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 20/20 1.00
WDR77 Q9BQA1 18/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23160280 1.00 PRMT5 (1.00) PRMT5WDR77
SCHEMBL29731535 1.00 PRMT5 (1.00) PRMT5WDR77
SCHEMBL23160673 0.91 PRMT5 (1.00) PRMT5WDR77
SCHEMBL29731301 0.91 PRMT5 (1.00) PRMT5WDR77
SCHEMBL23190429 0.91 PRMT5 (1.00) PRMT5WDR77
SCHEMBL29731190 0.88 PRMT5 (0.80) PRMT5WDR77
SCHEMBL23160131 0.88 PRMT5 (0.80) PRMT5WDR77
SCHEMBL28823704 0.88 PRMT5 (0.80) PRMT5WDR77
SCHEMBL23160168 0.88 PRMT5 (1.00) PRMT5WDR77
SCHEMBL23160171 0.88 PRMT5 (1.00) PRMT5WDR77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240051951-A1 BICYCLIC COMPOUND AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2024-02-15 US claimed
US-11725001-B2 Bicyclic compound and use thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2023-08-15 US claimed
US-20220402902-A1 BICYCLIC COMPOUND AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. 2022-12-22 US claimed
US-11111237-B2 Bicyclic compound and use thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2021-09-07 US claimed
WO-2021066578-A1 BICYCLIC COMPOUND AND USE THEREOF 에스케이바이오팜 주식회사 2021-04-08 WO claimed
US-20210101892-A1 BICYCLIC COMPOUND AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. 2021-04-08 US claimed
WO-2024101965-A1 PHARMACEUTICAL COMBINATION OF PRMT5 INHIBITOR AND DNA DAMAGE-INDUCING SUBSTANCE 에스케이바이오팜 주식회사 2024-05-16 WO disclosed
US-20240051951-A1 BICYCLIC COMPOUND AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2024-02-15 US disclosed
US-20230286965-A1 BICYCLIC COMPOUND AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2023-09-14 US disclosed
US-11725001-B2 Bicyclic compound and use thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2023-08-15 US disclosed
US-20220402902-A1 BICYCLIC COMPOUND AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. 2022-12-22 US disclosed
EP-4039686-A1 BICYCLIC COMPOUND AND USE THEREOF SK Biopharmaceuticals Co., Ltd. (KR) 2022-08-10 EP disclosed
US-11111237-B2 Bicyclic compound and use thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2021-09-07 US disclosed
WO-2021066578-A1 BICYCLIC COMPOUND AND USE THEREOF 에스케이바이오팜 주식회사 2021-04-08 WO disclosed
US-20210101892-A1 BICYCLIC COMPOUND AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. 2021-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220402902-A1 BICYCLIC COMPOUND AND USE THEREOF PRMT5, PRMT6, PRMT1 PRMT5 1/4885WDR77 85/4885
US-11111237-B2 Bicyclic compound and use thereof PRMT5, PRMT6, PRMT1 PRMT5 1/4885WDR77 85/4885
US-20240051951-A1 BICYCLIC COMPOUND AND USE THEREOF PRMT5, PRMT6, PRMT1 PRMT5 1/4885WDR77 85/4885
US-20210101892-A1 BICYCLIC COMPOUND AND USE THEREOF PRMT5, PRMT6, PRMT1 PRMT5 1/4885WDR77 85/4885
US-20230286965-A1 BICYCLIC COMPOUND AND USE THEREOF PRMT5, PRMT6, PRMT8 PRMT5 1/4885WDR77 93/4885
US-11725001-B2 Bicyclic compound and use thereof PRMT5, PRMT6, PRMT1 PRMT5 1/4885WDR77 85/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.